CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2097
Issued: 2026-10-17

PRODUCT IDENTIFICATION

PRODUCT		SKU / INTERNAL CODE
FOXO4-DRI 10 mg		CRF-2026-2097
PRESENTATION		BATCH NUMBER
Lyophilised powder, 10 mg vial		LOT-2610-2097
CLIENT	SAMPLE RECEIVED	ANALYSIS DATE
veltispeptides.mx	2026-10-12	2026-10-15
PRODUCTION DATE	ISSUED	EXPIRY / RETEST
2026-10-10	2026-10-17	2028-10-17

MOLECULAR FORMULA
D-retro-inverso peptide, 21 aa

MOLECULAR WEIGHT	CAS NUMBER
2957.5	N/A

ANALYTICAL METHOD

PANEL
SILVER - HPLC-UV + LC-MS/MS + ICP-MS (Pb/As/Cd/Hg) + LAL endotoxin

METHOD
RP-HPLC-UV 214 nm · LC-MS/MS ESI Q-TOF · ICP-MS · LAL kinetic chromogenic (USP <85>)

INSTRUMENT
Waters Xevo G3 · Agilent 7900 ICP-MS · Charles River Endosafe nexgen-PTS

Column: C4 2.1×100mm | Temperature: 55°C | Mobile phase: 0.1% TFA H2O / ACN | Flow: 0.3 mL/min | Retention time: 11.6 min

1. PURITY & ASSAY - RP-HPLC-UV (214 nm)

Test	Specification	Result	Status
HPLC Purity	≥98.0%	99.4%	PASS
Quantity	95.0-105.0%	9.97 mg (99.7%)	PASS

2. LC-MS/MS STRUCTURAL CONFIRMATION

Test	Reported data	Status
Theoretical [M+H]+	2958.5	Observed: 2958.8	Δ +0.30 Da	PASS
Sequence Coverage (MS/MS)	≥95%	96% (D-residues resist enzymatic cleavage - coverage by ESI-CID direct fragmentation)	PASS
Key fragments	b5 611.4 · b10 1187.7 · y6 723.4 · y11 1289.7	PASS
Modifications	all residues D-configuration confirmed by retention-time shift vs L-enantiomer reference (+1.4 min) and absence of chymotryptic cleavage sites	PASS

3. HEAVY METALS - ICP-MS (USP <232>/<233>)

Test	Specification	Result	Status
Pb	≤5.0 µg/g	<0.05 µg/g	PASS
As	≤15.0 µg/g	<0.10 µg/g	PASS
Cd	≤2.0 µg/g	<0.02 µg/g	PASS
Hg	≤3.0 µg/g	<0.01 µg/g	PASS

4. ENDOTOXIN - LAL kinetic chromogenic (USP <85>)

Test	Reported data	Status
Result	<1.0 EU/mg limit | 0.30 EU/mg | PPC recovery 79%	PASS

FINAL BATCH RESULT

PASS - Conforms to specifications

ANALYST NOTES

Senolytic peptide, retro-inverso D-configuration for protease resistance. Chiral integrity verified - no L-isomer contamination above 1.5% by chiral HPLC.

crafa

CRAFA